+
+
Stay Informed
TEER

TRICLIP™ TRANSCATHETER TRICUSPID VALVE REPAIR CLINICAL DATA

TriClip™ Transcatheter Edge-to-Edge repair offers a minimally invasive treatment option for patients with severe symptomatic tricuspid regurgitation (TR).

TEER

TRICLIP™ TRANSCATHETER TRICUSPID
VALVE REPAIR
CLINICAL DATA

TriClip™ Transcatheter Edge-to-Edge repair offers a minimally invasive treatment option for patients with severe symptomatic tricuspid regurgitation (TR).

THE STANDARD OF CARING FOR TR

TriClip TEER has shown meaningful outcomes in both real-world and randomized clinical data. The bRIGHT study and TRILUMINATE™ Pivotal Trial demonstrated the safety and effectiveness of TriClip TEER in the treatment of severe tricuspid regurgitation (TR).1,4

TRILUMINATE™ PIVOTAL TRIAL

Exceptional safety.1,2
Life-changing impact.1,4

The TRILUMINATE™ Pivotal Trial demonstrated that TriClip TEER Therapy was superior to medical therapy alone reducing risk of heart failure hospitalization and improving quality of life.

Remarkable and sustained TR reduction3

TR grade (Core Lab)

 

  • Exceptional safety at 30 days1,3

    98.9%

    FREEDOM
    FROM MAEs

    0.9%

    NEW PACEMAKER
    IMPLANTATION

    0%

    DEVICE THROMBUS

    99.6%

    SURVIVAL

    0%

    NONELECTIVE CV
    SURGERY FROM
    DEVICE-RELATED AE

    0%

    DEVICE EMBOLIZATION

  • Significant improvement in health-related quality of life3
  • Baseline population characteristics5

    73%

    OF PATIENTS HAD MASSIVE
    OR TORRENTIAL TR

    4.3±0.8cm

    TRICUSPID VALVE
    ANNULUS DIAMETER

    38%

    OF PATIENTS WITH PRIOR
    MITRAL OR AORTIC VALVULAR INTERVENTION

    17%

    OF PATIENTS HAD A CRT, CRT-D, ICD,
    OR PERMANENT PACEMAKER

bRIGHT STUDY

Proven across a broad
range of anatomies4,6

The bRIGHT Study demonstrated that TriClip™ TEER significantly reduced TR across a broad range of anatomies - in a safe and effective procedure - resulting in durable and meaningful clinical outcomes.

Designed to maximize TR reduction2,4,7

TR grade (Core Lab)

 

  • Successfully treated a broad range of anatomies6
  • Proven durability backed by clinical data

    NYHA Functional Class7

    KCCQ - OS Score2

  • TriClip TEER demonstrated procedural success and an exceptional safety profile8

    HIGH PROCEDURAL
    SUCCESS

    99.0%

    Implant
    sucess rate

    SHORT
    DEVICE TIME
     

    76±39

    Minutes

    HIGH SAFETY
    PROFILE
     

    97.5%

    Freedom
    from MAEs
    at 30 days



    99.0% survival at 30 days

    0.2% TV reintervention

    0.0% embolization

     

TRILUMINATE™ TRIAL

Proven safety and effectiveness

The TRILUMINATE™ Trial demonstrated that TriClip TEER safely and effectively reduces TR and HF hospitalizations. 

93%

SURVIVAL
AT 1 YR10

100%

IMPLANT
SUCCESS10

91%

ACUTE PROCEDURAL
SUCCESS RATE10

0%

STROKE10
AT 30 DAYS

0%

CONVERSION TO
SURGERY10
AT 30 DAYS

  • Significant and durable TR reduction11

    Durable reduction in tricuspid regurgitation (TR)

  • Significant improvement in functional status and quality of life11

    Durable improvements in NYHA


    ≥10-point KCCQ-OS score improvement was observed in 50% of subjects at three years.11

MAT-2006556 v13.0 | Item approved for OUS use only.

References
  1. Tang GHL, Hahn RT, Whisenant BK, et al. Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation: 1-year outcomes from the TRILUMINATE randomized cohort. J Am Coll Cardiol. Published online 2025;85(3):235-246. doi:10.1016/j.jacc.2024.10.08
  2. Lurz P, Rommel KP, Schmitz T, et al. Real-world 1-year results of tricuspid edge-to-edge repair from the bRIGHT study. J Am Coll Cardiol. 2024;84(7):607-616. doi:10.1016/j.jacc.2024.05.006
  3. Kar S, Makkar RR, Whisenant BK, et al. Two-year outcomes of transcatheter edge-to-edge repair for severe tricuspid regurgitation: The TRILUMINATE Pivotal Randomized Trial. Circulation. March 30, 2025. doi:10.1161/CIRCULATIONAHA.125.074536
  4. Estevez-Loureiro R. Real-world outcomes for tricuspid edge-to-edge repair: initial 2-year outcomes from the bRIGHT trial. Presented at PCR London Valves; November 19, 2023; London, England.
  5. Tang GHL, Hahn RT, Whisenant BK, et al. Tricuspid transcatheter edge-to-edge repair for severe tricuspid regurgitation: 1-year outcomes from the TRILUMINATE randomized cohort. J Am Coll Cardiol. Published online 2025; Suppl 1. Tables 1-13. doi:10.1016/j.jacc.2024.10.08
  6. Lurz P, Lapp H, Schueler R, et al. Real-world Outcomes for Tricuspid ​Edge-to-Edge Repair: Initial 30-Day Results from the TriClip™ bRIGHT Study. Presented at: EuroPCR; May 17-20, 2022; Paris, France​.
  7. Bekeredjian R. Real-World 2-Year Results of Tricuspid Edge-to-Edge Repair from the bRIGHT Study. Presented at EuroPCR 2025; Paris, France.
  8. Lurz P, Besler C, Schmitz T, et al. Short-term outcomes of tricuspid edge-to-edge repair in clinical practice. J Am Coll Cardiol. 2023;82(4):281-291. doi:10.1016/j.jacc.2023.05.008
  9. von Bardeleben RS, Lurz P, Sitges M, et al. Percutaneous edge-to-edge repair for tricuspid regurgitation: 2-year outcomes from the TRILUMINATE trial. Presented at: EuroPCR 2021.
  10. Lurz P, von Bardeleben RS, Weber M, et al. Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation. J Am Coll Cardiol. 2021;77(3):229-239.
  11. Nickenig G. Percutaneous edge-to-edge repair for tricuspid regurgitation: 3-year outcomes from the TRILUMINATE trial. Presented at PCR London Valves on November 19-21, 2023; London, UK.
Abbott Logo

Follow Abbott

Copyright © 2025 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
Caution: Product(s) are intended for use by or under the direction of a physician. Prior to use, reference to the Instructions for Use, inside the product carton (when available) or at www.eifu.abbott for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

MAT-2000631 v21.0 | Item approved for OUS use only.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

U.S. Health Care Professionals International Health Care Professionals

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

OkCancel
+